CCR 20th Anniversary Commentary: Divide and Conquer-Breast Cancer Subtypes and Response to Therapy.
The article by Rouzier and colleagues, published in the August 15, 2005, issue of Clinical Cancer Research, demonstrated that different molecular subtypes of breast cancer have different degrees of sensitivity to chemotherapy, but the extent of response to neoadjuvant therapy has a different meaning by subtype. Several molecular subtype-specific clinical trials are under way to maximize pathologic complete response rates in triple-negative breast cancer and HER2-positive cancers, and to provide adjuvant treatment options for patients with residual invasive disease. See related article by Rouzier et al., Clin Cancer Res 2005;11(16) Aug 15, 2005;5678-85.
Breast Medical Oncology, Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut. lajos.pusztai@yale.edu.
Lajos
L
Pusztai
Department of Surgery, Curie Institute, Paris, France.
Roman
R
Rouzier
Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
W Fraser
WF
Symmans
D000846:Anniversaries and Special Events; D001943:Breast Neoplasms / Q000145:classification / Q000188:drug therapy* / Q000235:genetics*; D005260:Female; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics*
D018719:Erb-b2 Receptor Tyrosine Kinases; C508053:ERBB2 protein, human